Compare CCEP & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCEP | EW |
|---|---|---|
| Founded | 1986 | 1958 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Industrial Specialties |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.9B | 50.2B |
| IPO Year | 2015 | 1999 |
| Metric | CCEP | EW |
|---|---|---|
| Price | $96.50 | $78.05 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 21 |
| Target Price | ★ $105.83 | $96.21 |
| AVG Volume (30 Days) | 1.9M | ★ 4.1M |
| Earning Date | 02-17-2026 | 04-23-2026 |
| Dividend Yield | ★ 2.42% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.83 |
| Revenue | N/A | ★ $6,067,600,000.00 |
| Revenue This Year | $4.76 | $13.39 |
| Revenue Next Year | $3.82 | $9.81 |
| P/E Ratio | ★ $20.93 | $42.69 |
| Revenue Growth | N/A | ★ 11.55 |
| 52 Week Low | $84.66 | $68.63 |
| 52 Week High | $110.90 | $87.89 |
| Indicator | CCEP | EW |
|---|---|---|
| Relative Strength Index (RSI) | 50.97 | 38.09 |
| Support Level | $89.03 | $77.60 |
| Resistance Level | $100.67 | $78.64 |
| Average True Range (ATR) | 1.95 | 1.96 |
| MACD | 0.65 | -0.33 |
| Stochastic Oscillator | 71.22 | 15.32 |
CCEP is the second-largest bottling partner in the Coca-Cola system by volume, behind Coca-Cola Femsa, and primarily operates in developed Europe, Australasia, and Southeast Asia. In 2025, CCEP sold 3.9 billion unit cases of beverages, which we estimate equates to roughly 9% of the global Coke system volume.TCCC owns 19% of the equity of CCEP, Olive Partners, a holding company of bottling operations, owns a further 36%, and the remaining 45% is free float.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.